Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Receivables (2016 - 2025)

Altimmune (ALT) has disclosed Change in Receivables for 16 consecutive years, with $524000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 13000.0% to $524000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $417000.0, a 192.87% increase, with the full-year FY2024 number at -$567000.0, down 160.45% from a year prior.
  • Change in Receivables was $524000.0 for Q3 2025 at Altimmune, up from -$186000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $741000.0 in Q3 2023 to a low of -$3.1 million in Q3 2021.
  • A 5-year average of -$198157.9 and a median of $3000.0 in 2022 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: plummeted 4000.0% in 2023, then soared 13000.0% in 2025.
  • Altimmune's Change in Receivables stood at -$1.1 million in 2021, then surged by 59.83% to -$460000.0 in 2022, then skyrocketed by 150.87% to $234000.0 in 2023, then crashed by 50.43% to $116000.0 in 2024, then surged by 351.72% to $524000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Change in Receivables are $524000.0 (Q3 2025), -$186000.0 (Q2 2025), and -$37000.0 (Q1 2025).